Quantcast

Latest human disease Stories

2009-07-21 05:30:00

THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan drug designation from the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome....

2009-07-07 05:30:00

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors....

2009-04-28 05:30:00

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, April 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2009. "Our pipeline of novel drug candidates continues to advance in line with our expectations," said Dr. Arthur...

2009-04-16 09:55:21

Database provides a key to unlock the causes of illnesses Today - five years after the inception of the DECIPHER database - researchers have published a report that reveals the developing role of the database in revolutionizing both clinical practice and genetic research. The report explores the growing benefits of DECIPHER for researchers, clinicians and patients - highlighting how the data, provided by around 100 centers and shared openly worldwide, can benefit all three groups. DECIPHER -...

2008-11-13 06:00:08

* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid Patients * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has successfully completed a second Phase 1 clinical trial of...

2005-12-07 18:00:00

By Toni Clarke BOSTON -- How can a Chihuahua and a Doberman belong to the same species? A detailed analysis of the dog genome answers these questions and will also shed light on human health and biology, scientists said on Wednesday. A U.S. government-funded study of the complete genetic map of an inbred boxer named Tasha not only helps explain how poodles differ from jackals, but might offer insights into bone cancer, blindness and epilepsy, the researchers said. "It's going to make the...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.